Jefferies analyst Tycho Peterson assumed coverage of Quest Diagnostics (DGX) with a Buy rating and a price target of $185, up from $175. Larger full-service reference labs, such as Quest, stand to benefit from the same tailwinds as “esoteric labs,” but with less idiosyncratic National Provider Identifier commercialization and reimbursement risk, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics management to meet with Piper Sandler
- Quest Diagnostics price target raised to $165 from $150 at Piper Sandler
- Quest Diagnostics price target raised to $175 from $163 at Argus
- Quest Diagnostics price target raised to $174 from $160 at Mizuho
- Snap upgraded, McDonald’s downgraded: Wall Street’s top analyst calls